An Open-label, Single-arm, Multicenter, Phase II Clinical Study of the Efficacy and Safety of Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Patients With Untreated Advanced Pancreatic Cancer
Latest Information Update: 04 Jun 2025
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Serplulimab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Therapeutic Use
Most Recent Events
- 01 Jun 2025 According to a Shanghai Henlius Biotech media release, data from this study presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 20 Dec 2024 According to a Henlius Biopharmaceuticals Media Release, data from this study were presented at the APA/JPS/CAP/IAP 2024 Annual Meeting.
- 20 Dec 2024 Results presented in a Henlius Biopharmaceuticals Media Release.